DK3653644T3 - Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft - Google Patents
Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft Download PDFInfo
- Publication number
- DK3653644T3 DK3653644T3 DK19205321.3T DK19205321T DK3653644T3 DK 3653644 T3 DK3653644 T3 DK 3653644T3 DK 19205321 T DK19205321 T DK 19205321T DK 3653644 T3 DK3653644 T3 DK 3653644T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- cachesia
- gdf
- treatment
- monoclonal antibodies
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 2
- 230000004069 differentiation Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1405477.9A GB2524553C (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
GB1405475.3A GB2524552B (en) | 2014-03-26 | 2014-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
EP15712629.3A EP3122775B1 (en) | 2014-03-26 | 2015-03-26 | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3653644T3 true DK3653644T3 (da) | 2023-12-18 |
Family
ID=52745885
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15712629.3T DK3122775T3 (da) | 2014-03-26 | 2015-03-26 | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
DK19205321.3T DK3653644T3 (da) | 2014-03-26 | 2015-03-26 | Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15712629.3T DK3122775T3 (da) | 2014-03-26 | 2015-03-26 | Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer |
Country Status (22)
Country | Link |
---|---|
US (5) | US20170204174A1 (da) |
EP (3) | EP3653644B1 (da) |
JP (3) | JP6865585B2 (da) |
KR (1) | KR102520978B1 (da) |
CN (1) | CN106536553B (da) |
AU (2) | AU2015238264B2 (da) |
BR (1) | BR122023027559A2 (da) |
CA (1) | CA2943694A1 (da) |
CY (1) | CY1122456T1 (da) |
DK (2) | DK3122775T3 (da) |
ES (2) | ES2965626T3 (da) |
FI (1) | FI3653644T3 (da) |
HR (2) | HRP20231514T1 (da) |
HU (2) | HUE047398T2 (da) |
IL (2) | IL248038B (da) |
LT (2) | LT3122775T (da) |
NZ (1) | NZ724649A (da) |
PL (2) | PL3122775T3 (da) |
PT (2) | PT3653644T (da) |
RS (1) | RS59700B1 (da) |
SI (1) | SI3122775T1 (da) |
WO (1) | WO2015144855A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE047398T2 (hu) | 2014-03-26 | 2020-04-28 | Univ Wuerzburg J Maximilians | Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére |
WO2016049470A1 (en) | 2014-09-25 | 2016-03-31 | Aveo Pharmaceuticals, Inc. | Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent |
GB201517528D0 (en) * | 2015-10-02 | 2015-11-18 | Julius Maximillians Universitãt Würzburg | GDF-15 as a diagnosis marker for melanoma |
AU2016333538B2 (en) * | 2015-10-02 | 2022-03-31 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
WO2017055613A2 (en) * | 2015-10-02 | 2017-04-06 | Julius-Maximilians-Universität Würzburg | Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers |
US11312766B2 (en) | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
CA3029136A1 (en) * | 2016-07-06 | 2018-01-11 | National Research Council Of Canada | Humanized antibodies transmigrating the blood-brain barrier and uses thereof |
WO2018071493A1 (en) * | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
AU2017371382A1 (en) * | 2016-12-06 | 2019-06-13 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
TWI803682B (zh) * | 2018-08-20 | 2023-06-01 | 美商輝瑞股份有限公司 | 抗-gdf15抗體、組成物及使用方法 |
WO2022101263A1 (en) * | 2020-11-10 | 2022-05-19 | Catalym Gmbh | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
MX2023011655A (es) | 2021-03-31 | 2023-10-11 | Cambridge Entpr Ltd | Inhibidores terapeuticos de la se?alizacion de gdf15. |
AU2022328390A1 (en) | 2021-08-10 | 2024-03-21 | Adimab, Llc | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
WO2023217068A1 (zh) * | 2022-05-09 | 2023-11-16 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
JP2002543841A (ja) | 1999-05-17 | 2002-12-24 | バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー | TGF−βスーパーファミリーの新規のメンバーであるGDF―15の神経保護特性 |
AU2001288770A1 (en) | 2000-09-08 | 2002-03-22 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
HUE026132T2 (en) * | 2004-01-07 | 2016-05-30 | Novartis Vaccines & Diagnostics Inc | M-CSF-specific monoclonal antibody and its uses |
WO2005099746A1 (en) | 2004-04-13 | 2005-10-27 | St Vincent's Hospital Sydney Limited | Method for modulating appetite |
US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
JP2011502106A (ja) * | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−1を除去又は不活性化して悪液質を治療する方法 |
CN102164959A (zh) | 2008-09-29 | 2011-08-24 | 罗氏格黎卡特股份公司 | 针对人il17的抗体及其应用 |
WO2011050407A1 (en) | 2009-10-28 | 2011-05-05 | St Vincent's Hospital Sydney Limited | Methods of diagnosing and prognosing colonic polyps |
US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
PT2644698T (pt) * | 2010-11-17 | 2018-01-31 | Chugai Pharmaceutical Co Ltd | Molécula multiespecífica de ligação ao antigénio com uma função alternativa à função do fator viii de coagulação do sangue |
US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
EP2565262A1 (en) | 2011-08-31 | 2013-03-06 | VTU Holding GmbH | Protein expression |
EP2807266B1 (en) | 2012-01-26 | 2020-01-15 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
TR201910744T4 (tr) * | 2012-09-26 | 2019-08-21 | Univ Wuerzburg J Maximilians | Büyüme ve farklılaşma faktörü 15 e (gdf-15) yönelik monoklonal antikorlar. |
DK2934584T3 (da) | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | Anti-gdf15-antistoffer |
HUE047398T2 (hu) | 2014-03-26 | 2020-04-28 | Univ Wuerzburg J Maximilians | Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére |
-
2015
- 2015-03-26 HU HUE15712629A patent/HUE047398T2/hu unknown
- 2015-03-26 PL PL15712629T patent/PL3122775T3/pl unknown
- 2015-03-26 NZ NZ724649A patent/NZ724649A/en unknown
- 2015-03-26 CN CN201580027932.8A patent/CN106536553B/zh active Active
- 2015-03-26 PL PL19205321.3T patent/PL3653644T3/pl unknown
- 2015-03-26 LT LTEP15712629.3T patent/LT3122775T/lt unknown
- 2015-03-26 HU HUE19205321A patent/HUE064573T2/hu unknown
- 2015-03-26 WO PCT/EP2015/056654 patent/WO2015144855A1/en active Application Filing
- 2015-03-26 DK DK15712629.3T patent/DK3122775T3/da active
- 2015-03-26 AU AU2015238264A patent/AU2015238264B2/en active Active
- 2015-03-26 CA CA2943694A patent/CA2943694A1/en active Pending
- 2015-03-26 LT LTEP19205321.3T patent/LT3653644T/lt unknown
- 2015-03-26 EP EP19205321.3A patent/EP3653644B1/en active Active
- 2015-03-26 PT PT192053213T patent/PT3653644T/pt unknown
- 2015-03-26 ES ES19205321T patent/ES2965626T3/es active Active
- 2015-03-26 SI SI201531059T patent/SI3122775T1/sl unknown
- 2015-03-26 RS RS20191652A patent/RS59700B1/sr unknown
- 2015-03-26 DK DK19205321.3T patent/DK3653644T3/da active
- 2015-03-26 PT PT157126293T patent/PT3122775T/pt unknown
- 2015-03-26 KR KR1020167029710A patent/KR102520978B1/ko active IP Right Grant
- 2015-03-26 ES ES15712629T patent/ES2763859T3/es active Active
- 2015-03-26 JP JP2016559286A patent/JP6865585B2/ja active Active
- 2015-03-26 EP EP15712629.3A patent/EP3122775B1/en active Active
- 2015-03-26 BR BR122023027559-4A patent/BR122023027559A2/pt unknown
- 2015-03-26 HR HRP20231514TT patent/HRP20231514T1/hr unknown
- 2015-03-26 US US15/128,604 patent/US20170204174A1/en not_active Abandoned
- 2015-03-26 FI FIEP19205321.3T patent/FI3653644T3/fi active
- 2015-03-26 EP EP23203704.4A patent/EP4316596A3/en active Pending
-
2016
- 2016-09-26 IL IL248038A patent/IL248038B/en active IP Right Grant
-
2018
- 2018-03-05 US US15/912,358 patent/US10604565B2/en active Active
-
2020
- 2020-01-08 CY CY20201100008T patent/CY1122456T1/el unknown
- 2020-01-09 HR HRP20200034TT patent/HRP20200034T1/hr unknown
- 2020-02-19 US US16/794,406 patent/US11760795B2/en active Active
- 2020-02-19 US US16/794,401 patent/US11634482B2/en active Active
- 2020-07-30 IL IL276405A patent/IL276405B/en unknown
- 2020-10-28 AU AU2020260440A patent/AU2020260440B2/en active Active
-
2021
- 2021-04-06 JP JP2021064572A patent/JP2021119138A/ja active Pending
-
2023
- 2023-04-06 JP JP2023062338A patent/JP2023098966A/ja active Pending
- 2023-08-02 US US18/364,173 patent/US20230382987A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3653644T3 (da) | Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft | |
DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
HK1245134A1 (zh) | 用抗lap單克隆抗體治療癌症 | |
DK3565844T3 (da) | Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer | |
DK3307322T3 (da) | Humaniserede anti-cd40-antistoffer og anvendelser deraf | |
DK3508502T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3303395T3 (da) | Anti-cd40-antistoffer og anvendelser deraf | |
DK3504242T3 (da) | Anti-ox40-antistoffer og anvendelse deraf | |
DK3142751T3 (da) | Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer | |
DK3274370T3 (da) | Anti-ceacam6-antistoffer og anvendelser deraf | |
SG11201705585QA (en) | Anti-myostatin antibodies and methods of use | |
IL264674B1 (en) | Antibodies to siglec7 for cancer treatment | |
DK3474841T3 (da) | Fremgangsmåder til behandling af ar+-brystkræft | |
DK3280440T3 (da) | Humaniserede anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
DK3114142T3 (da) | Insulinlignende vækstfaktor 1-receptorspecifikke antistoffer og anvendelser deraf | |
DK3445785T3 (da) | Humaniserede anti-clever-1-antistoffer og anvendelse deraf | |
IL258515A (en) | Treatment methods using anti-il-17a/f antibodies | |
DK3209686T3 (da) | Monoklonale anti-gpc-1-antistoffer og anvendelser deraf | |
DK3349731T3 (da) | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft | |
DK3313528T3 (da) | Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer | |
GB2524553C (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia | |
GB2524552B (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |